ClinicalTrials.gg
RecruitingNCT02381990FIPCUpdated Jan 26, 2023

MRI/Ultrasound Fusion Guided Prostate Cryotherapy

An observational study in Neoplasms Prostate and Cancer of the Prostate, sponsored by Urological Research Network, LLC. Recruiting at 1 site in United States. Open to male participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Urological Research Network, LLC · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2023, 3 years 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2013; still recruiting 13 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
55 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
27th of 478
5,000 · median 158
Started
2013
with 122 others
Observational
483 of 3,597
100 open now
Primary completion
2023-08
later than 51 of 968 live
Registered
1,718th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 27th largest by planned enrollment of the 478 observational ones that give a count, is one of 123 that started in 2013, is one of 483 observational ones, reaches primary completion later than 51 of the 968 other live ones, and was the 1,718th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 55 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Registration of Prostate Cancer patients undergoing Prostate Cryotherapy guided by Mutiparametric-MRI (MP-MRI) highlighting biopsy confirmed regions. The primary outcome measure is 5 year oncological control. Secondary aim is lack of progression beyond the prostate gland. The aim of intervention is to eradicate prostate cancer disease in the treated area while imposing no or minimal deleterious effects in quality of life.

Read the detailed description

CLINICAL TRIAL OF OBSERVATION NATURE

PRIMARY OUTCOME

Cancer control of treated areas 5, 10, 15 years after intervention based on prostate biopsy of initial treated area, progression requiring conversion to radical prostate surgery or radiation or other forms of whole gland treatment (ej, HIFU), Metastatic Free survival: CT Scan and Bone Scans, Cancer-Specific and Overall Survival

SECONDARY OUTCOMES

Secondary Interventions focal interventions due to de-novo lesions. Focal or target therapy rescue with other technologies (ej HIFU); Short, Intermediate and Long-Term Urinary and Sexual Function changes in quality of life measured by validated inventories; Anxiety related to cancer and cancer control. Treatment tolerance to local anesthesia. Patient App compliance and activity to monitor care

DATA COLLECTION

  • Complete H\&P, family history, past medical and surgical history, social history, allergies, and medications
  • As of July 2016, voluntary measurement thru Focalyx App for smartphones and tablets
  • Imaging Specifics Assessing Prostate, Seminal Vesicles and Urethral Contouring by Multi-parametric-MRI. Dominant lesions and secondary lesions contouring my MP-MRI.
  • Procedure specific Co-Registration quality with ultrasound denoting quality
  • Specific ablative description and digitalization of critical measures such as: ablation type (ej cryotherapy, equipment used) procedure, cryoprobes used, freeze/thaw cycles timing, temperatures at neurovascular bundles, denonvilliers fascia. Urethral warmer requirements
  • Follow up information: 30 day perioperative outcomes (incidence of UTI, urinary retention, failure of local anesthetic, pain measures). 6 week, 3,6,9,12 month and then every 6 month measures of PSA, Testosterone levels, Urinary Function and Sexual Function inventories, Overall anxiety and regret related to diagnosis and treatment
  • Uroflow and PVR measurements by 3 to 6 month of treatment
  • MP MRI on a yearly basis, for years 2,3,4 after treatment, biopsy driven by new suspicious MRI findings
  • MP MRI triggered by elevation in PSA velocity or PSA level 10% above diagnosis
  • Transperineal Fusion Guided Prostate biopsy at 1st year - emphasis on treated areas, suspicious MRI areas
  • Transperineal Fusion Guided Prostate biopsy at 5th year - emphasis on treated areas, suspicious MRI areas
  • 5, 10, 15 Yr CT Scans, PET Scan/Bone Scan

SAFETY MEASURES

  • Periodic evaluation of registry to ensure consistency in follow up
  • Patient remainders of tests required
03

Conditions studied

  • Neoplasms Prostate
  • Cancer of the Prostate

Keywords

  • Prostate
  • PSA
  • FUSION
  • Ultrasound
  • MRI
  • Cancer
  • Cryotherapy
  • Outcomes
  • Recurrence
  • QOL, Quality of Life
  • Urinary function
  • Sexual Function
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

As written in Initial Section

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men between 55 and 65 years of age with a clinical diagnosis of prostate cancer with Low or Intermediate risk prostate cancer, and \<50% positive core rate by prostate lobe
  • Men older than 65 years of age with clinical diagnosis of prostate cancer \<50% positive core rate by prostate lobe
  • Absence of extra-capsular extension
  • Absence of seminal vesicle invasion
  • Absence of regional or distant disease
  • Multiparametric MRI of the prostate performed either before the or >10 weeks after prostate biopsy
  • Treated with Cryotherapy of the prostate
  • Treatment based on co-registration between MP-MRI and Prostate Ultrasound

Exclusion criteria

Exclusion Criteria:

  • Prior treatment of prostate cancer in the form of surgery.
  • Performance status greater than 0 based on criteria
  • Mental status impairment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Interventions

  • ProcedureFUSE IMAGE MRI GUIDED PROSTATE CRYOTHERAPY

    Biopsy proven Prostate Cancer is delimited and defined by MP-MRI. The MRI study is fused with transrectal ultrasound in realtime. The cryogenic "cryoprobes/devices" are employed to freeze and all "circuled or noted" cancer lesions. Two freeze 8 min/ thaw 10 min clycles are performed. Thermocouples are used to monitor treatment areas and safety margins

    Also known as: Intervention of Interest: Prostate Cryoablation

06

What researchers measure

Primary outcomes

  1. Oncological Control

    Lack of prostate cancer presence in treated area after MRI/US FUSION Biopsy

    Time frame: 1 Year

Secondary outcomes

  1. Oncological Control

    Lack of prostate cancer presence in the gland after MRI/US FUSION Biopsy

    Time frame: 1 Year

  2. Oncological Control

    Lack of prostate cancer presence in gland measured by MP-MRI

    Time frame: Yearly, up to 10 years

  3. Urinary Functional Outcomes

    Evaluation of urinary function outcomes when compared to baseline using expanded prostate composite index and AUA symptoms scores. Urinary function also by objective measurements - uroflow and post void residuals

    Time frame: Every 3 months up to 24 months

  4. Perioperative Outcomes

    Procedure tolerance, need for hospital admission or ER consultation, incidence of urinary tract infection, urinary retention, any significant side effect that may occur and perioperative survivel

    Time frame: 30 days

  5. Sexual Functional Outcomes

    Evaluation of sexual function outcomes when compared to baseline using Sexual Inventory for men questionnaires

    Time frame: Every 3 months up to 24 months

Other outcomes

  1. Secondary Treatment Requirement

    Type of treatments required after initial intervention over time

    Time frame: Yearly, up to 10 years

07

Study locations

1 of 1 sites recruiting
  • Urological Research Network
    Miami Lakes, Florida 33016, United States
    Recruiting
    • CIELO D GUERRA, BS · ContactCIELO@BESTUROLOGY.NET · 305-515-9887
    • FERNANDO J BIANCO, MD · Principal investigator
    • EDWARD L GHEILER, MD · Sub investigator
    • ARIEL M KAUFMAN, MD · Sub investigator
    • EUSEBIO J LUNA, MD · Sub investigator
08

References and documents

Publications

  • Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Futterer JJ, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y; START Consortium. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013 Oct;64(4):544-52. doi: 10.1016/j.eururo.2013.03.030. Epub 2013 Mar 20. PubMed 23537686 ↗
  • Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, Lieskovsky G, Ukimura O. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol. 2012 Jul;62(1):55-63. doi: 10.1016/j.eururo.2012.03.006. Epub 2012 Mar 21. PubMed 22445223 ↗
  • Costa DN, Pedrosa I, Donato F Jr, Roehrborn CG, Rofsky NM. MR Imaging-Transrectal US Fusion for Targeted Prostate Biopsies: Implications for Diagnosis and Clinical Management. Radiographics. 2015 May-Jun;35(3):696-708. doi: 10.1148/rg.2015140058. Epub 2015 Mar 18. PubMed 25786055 ↗
  • Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Futterer JJ; European Society of Urogenital Radiology. ESUR prostate MR guidelines 2012. Eur Radiol. 2012 Apr;22(4):746-57. doi: 10.1007/s00330-011-2377-y. Epub 2012 Feb 10. PubMed 22322308 ↗
  • Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, Merino MJ, Simon RM, Choyke PL, Wood BJ, Pinto PA. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015 Jan 27;313(4):390-7. doi: 10.1001/jama.2014.17942. PubMed 25626035 ↗

Individual participant data

Plan to share: Yes — Non identifiable pertinent information will be shared for other scientists to evaluate other pertinent questions

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2013 (actual). Primary completion is estimated for Aug 2023, 120 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 120 months is above that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2015
First posted
Mar 6, 2015
StartActual
Aug 2013
Primary completionEst.
Aug 2023
CompletionEst.
Aug 2033
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02381990
Lead sponsor
Urological Research Network, LLC
Responsible party
Sponsor
First posted
Mar 6, 2015
Start date
Aug 2013
Primary completion
Aug 2023 (estimated)
Completion
Aug 2033 (estimated)
Last update
Jan 26, 2023

Study contacts

CIELO D GUERRA, BS
Contact
CIELO@BESTUROLOGY.NET
305-515-9887
LUANDA SIANO, PA
Contact
LUANDA@BESTUROLOGY.NET
305-822-7227
FERNANDO J BIANCO, MD
principal investigator · UROLOGICAL RESEARCH NETWORK
EUSEBIO LUNA, MD
study director · UROLOGICAL RESEARCH NETWORK
Isabel H Lopez, MD
study director · UROLOGICAL RESEARCH NETWORK

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion